|Mr. Michael Stubblefield||Pres, CEO & Director||2.72M||N/A||1972|
|Mr. Thomas A. Szlosek||Exec. VP & CFO||271.15k||N/A||1964|
|Dr. Gerald Brophy Ph.D.||Exec. VP of Biopharma Production||357.58k||N/A||1966|
|Mr. Frederic Vanderhaegen||Exec. VP of Europe||214.35k||N/A||1967|
|Tanya Foxe||Exec. VP of Global Operations & Supply Chain||N/A||N/A||N/A|
Avantor, Inc. develops, customizes, manufactures, and supplies products and services to customers in the biopharma, healthcare, education and government, and advanced technologies and applied materials industries. The company's materials and consumables include ultra-high purity chemicals and reagents, lab products and supplies, formulated silicone materials, customized excipients, customized single-use assemblies, and process chromatography resins and columns, as well as analytical sample prep, education, and microbiology and clinical trial kits. Its equipment and instrumentation products comprise filtration systems, virus inactivation systems, incubators, analytical instruments, evaporators, ultra-low-temperature freezers, biological safety cabinets, and environment supplies. The company also provides onsite lab and production, clinical, equipment, procurement and sourcing, and biopharmaceutical material scale-up and development services. Avantor, Inc. was founded in 1904 and is headquartered in Radnor, Pennsylvania.
Avantor, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.